Haoxi Health Technology Ltd (HAO) FinancialsHAOFinancialHaoxi Health Technology Ltd

Evaluating the bottom line, Haoxi Health Technology Ltd maintains a gross margin of 4.72%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -16.79%, while the net margin is -20.34%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively HAO converts its operational activities into shareholder value.

In the context of the broader market, HAO competes directly with industry leaders such as DRCT and YHC. With a market capitalization of $1.94M, it holds a significant position in the sector. When comparing efficiency, HAO's gross margin of 4.72% stands against DRCT's 34.00% and YHC's 4.17%. Such benchmarking helps identify whether Haoxi Health Technology Ltd is trading at a premium or discount relative to its financial performance.

Haoxi Health Technology has shown a gross margin of 4.72% in the latest quarter, which is relatively low, and its EPS for 2026/Q2 is -196.26, indicating a substantial loss. The current ratio has also decreased to 3.45, suggesting potential liquidity issues.